Citigroup Adjusts Price Target on ResMed to $340 From $345, Maintains Buy Rating

NodeGuardian · 2026-04-08T11:33:48+00:00

Citigroup has lowered its price target for ResMed (RMD) from $345 to $340 while maintaining a "Buy" rating, reflecting continued optimism for the company's stock despite the lack of detailed reasons for the adjustment.

NodeGuardian

2026-04-08 11:33:48

Abstract generation in progress

Citigroup has adjusted its price target for ResMed (RMD) to $340, down from $345, while reiterating a “Buy” rating on the stock. The article, primarily a brief announcement, does not provide details on the reasons for the target price modification but confirms Citigroup’s sustained positive outlook for the company’s shares. ResMed specializes in medical devices and software for respiratory disorders.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.